secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2024-08-20T23:59:59+00:00
Accession:  0001367644-24-000152
Event type: m_and_a
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSciences closes sale of Baltimore-Camden facility to Bora for $30M
------------------------------------------------------------------------------

- Sold drug product facility in Baltimore-Camden to affiliate of Bora Pharmaceuticals (TWSE:6472) for ~$30M at closing.
- Bora acquired all assets, equipment, and workforce associated with the 87,000 sq ft facility.
- CEO Joe Papa says sale is a step in multi-year plan to stabilize, improve profitability, and reduce debt.
- Truist Securities and Covington & Burling advised Emergent on the transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000152/0001367644-24-000152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000152/ebs-20240820.htm
  HTML page:      https://secwatch.observer/filing/0001367644-24-000152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer